Patient, Provider and Caregiver Connection™: Individualizing Care in Hemophilia A—Understanding Patient Challenges and the Role of Innovative Treatment
October 5, 2020
October 5, 2021
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®.
This activity is supported by an educational grant from Bayer Healthcare.
- Physicians — maximum of 1.50 AMA PRA Category 1 Credit(s)™
- Nurses — 1.50 Contact Hours
All other health care professionals completing this course will be issued a statement of participation.
This online educational activity is directed toward hematologists, nurse practitioners, PAs, and other healthcare professionals involved in the treatment of patients with Hemophilia.
Over the past 20 years, substantial advances in the treatment of hemophilia A have allowed patients to take greater control of their disease. The primary goals of hemophilia A treatment are to prevent bleeding episodes, reduce long-term complications of bleeding, and arrest bleeding if it occurs. The mainstay of therapy for patients with hemophilia A is supplementation of the missing factor VIII (FVIII) proteins; however, over time patients can develop neutralizing antibodies to factor VIII concentrates. These alloantibodies, often referred to as inhibitors, reduce the effectiveness of therapy and significantly increase morbidity and mortality. Inhibitors pose a significant challenge in the treatment of hemophilia A, making management of bleeding episodes difficult and surgical procedures very challenging. Health care providers should understand the underlying etiology and pathophysiology of hemophilia A. In addition, providers should be familiar with how patients perceive their disease and how health-related and economic burdens of hemophilia A impact patients and their families.
In this activity, a patient with hemophilia A and his caregiver discuss the impact that his disease has on their family. Our expert faculty discuss the range of available, new, and emerging therapies for hemophilia A, as well as the problem of inhibitor development.
Upon successful completion of this activity, you should be better prepared to:
- Review guidelines and recommendations for the management of acute and prophylactic care of bleeding episodes, hemorrhagic complications, and inhibitor development in patients with hemophilia A
- Develop individualized treatment plans for hemophilia A based on patient-dependent factors
- Examine the burden and impact of hemophilia A on the patient including their own perspectives
Shannon L. Meeks, MD
Professor of Pediatrics
Emory University School of Medicine
Medical Director of Hemostasis/Thrombosis
Aflac Cancer and Blood Disorders Center
Children’s Healthcare of Atlanta
Janice Staber, MD
Assistant Professor of Pediatrics
Stead Family Department of Pediatrics
Division of Hematology/Oncology
University of Iowa Carver College of Medicine
Iowa Hemophilia and Thrombosis Center
University of Iowa Stead Family Children’s Hospital
Iowa City, IA
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Disclosures of Conflicts of Interest
In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Shannon L. Meeks, MD
- Grant/Research Support: National Institutes of Health, Hemophilia of Georgia, National Hemophilia Foundation
- Consultant: Spark Therapeutics, Sangamo Therapeutics, Pfizer, Sanofi, CSL Behring, Genentech, Takeda
Janice Staber, MD
- Consultant: Sanofi, Takeda
Asher Castenson (Patient) has no relevant financial relationships with commercial interests.
Julie Castenson (Caregiver) has no relevant financial relationships with commercial interests.
The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.
Instructions for Participation/How to Receive Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.